









Markets
/
Stocks
/
nasdaq-ug
/

United-Guardian Inc

7.950USD

+0.020+0.25%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

36.52MMarket Cap

14.28P/E TTM



United-Guardian Inc

7.950

+0.020+0.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

96 / 175

Overall Ranking

295 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

United-Guardian, Inc. is engaged in manufacturing and marketing cosmetic ingredients, pharmaceutical products, medical lubricants and sexual wellness ingredients. Cosmetic ingredients include a line of multifunctional hydrogel formulations designed to offer sensory enhancement, lubrication, texture and moisturization to personal care products. Its cosmetic ingredients include Lubrajel Natural, Lubrajel Marine, Lubrajel Oil Natural and Lubrajel Terra. Medical lubricants include a line of hydrogel formulations designed to offer sensory enhancement and lubrication to medical products. Pharmaceutical products include an FDA approved prescription drug that is used primarily to prevent and to dissolve calcifications in urethral catheters, as well as a chlorine-based topical antimicrobial. Sexual wellness ingredients include a line of hydrogel formulations designed to offer sensory enhancement, lubrication and moisturization to sexual wellness applications.

Growing

The company is in a growing phase, with the latest annual income totaling USD 12.18M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 26.52.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 84.79%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 84.79%.

Fairly Valued

The company’s latest PE is 14.28, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 2.69M shares, decreasing 2.32% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 187.96K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 9.37, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 2.84M, representing a year-over-year decrease of 16.28%, while its net profit experienced a year-over-year decrease of 34.45%.

Score

Industry at a Glance

Previous score

9.37

Change



Financials

9.33

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

9.86

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 5.18, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 14.25, which is 18.12% below the recent high of 16.83 and 0.90% above the recent low of 14.12.

Score

Industry at a Glance

Previous score

5.18

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 96/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Pharmaceuticals industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.23, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 8.54 and the support level at 7.56, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.23

Change

0.03

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.095

Sell

RSI(14)

43.874

Neutral

STOCH(KDJ)(9,3,3)

20.802

Neutral

ATR(14)

0.286

Low Volatility

CCI(14)

-102.262

Sell

Williams %R

84.615

Oversold

TRIX(12,20)

-0.032

Sell

StochRSI(14)

19.316

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

8.000

Sell

MA10

8.141

Sell

MA20

8.239

Sell

MA50

8.312

Sell

MA100

8.255

Sell

MA200

9.039

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 5.00, which is lower than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 58.59%, representing a quarter-over-quarter increase of 0.35%. The largest institutional shareholder is James Simons, holding a total of 187.96K shares, representing 4.09% of shares outstanding, with 1.16% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Globus (Kenneth H)

1.32M

Parker (Betsee)

310.59K

-7.87%

Gabelli Funds, LLC

195.50K

-0.51%

Renaissance Technologies LLC

Star Investors

188.96K

-0.63%

The Vanguard Group, Inc.

Star Investors

150.40K

+9.49%

Monongahela Capital Management

93.63K

-1.83%

Dimensional Fund Advisors, L.P.

76.88K

+2.51%

Teton Advisors, Inc.

54.16K

Parthenon LLC

51.91K

Geode Capital Management, L.L.C.

32.85K

+5.07%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.25, which is lower than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.